Radiation Therapy News and Research

RSS

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.

Galera Therapeutics completes Series 1 financing

Galera Therapeutics, a drug development company focused on novel therapeutics to protect against the side effects and increase the effectiveness of cancer treatment, today announced it has completed a Series 1 financing led by BioGenerator. Also participating in the round is Galera Angels, LLC, an angel investment group, and Analytical Bio-Chemistry Laboratories, Inc., of Columbia Missouri.

16 Jun 2010

NBC's TODAY Show to focus on PF in an interview with a patient from California

The Coalition for Pulmonary Fibrosis announced today one of the first major national media coverage opportunities for the CPF and Pulmonary Fibrosis. NBC's TODAY Show will focus on the disease in an interview with California patient Bob O'Rourke, who suffers from the disease and will die from it unless he receives a lung transplant in time.

15 Jun 2010

Xoft reports clinical benefits of isotope-free electronic radiation therapy for treatment of cancer

The clinical benefits of isotope-free electronic radiation therapy delivered directly to cancer sites with minimal exposure to surrounding healthy tissue continues to be substantiated by multiple publications, according to Xoft, Inc., developer of the Axxent Electronic Brachytherapy, eBx System. The leading provider of FDA-cleared Electronic Brachytherapy Systems, Xoft provides systems for single-dose intraoperative radiation therapy and accelerated brachytherapy applications.

15 Jun 2010

HL survivors do not receive recommended cancer screening tests: Study

A population-based study of 2,071 Hodgkin lymphoma survivors over 15 years has discovered that while many survivors had multiple X-rays and CT scans years after treatment was finished, they often did not receive recommended cancer screening tests.

11 Jun 2010

SBUMC uses RapidArc radiotherapy technology to treat cancer patients

A breakthrough external beam radiotherapy technology that is fast, precise, and has optimal dose delivery to targeted tumors while limiting damage to surrounding normal tissue, is the latest radiotherapy weapon that cancer specialists are using at Stony Brook University Medical Center to treat patients.

11 Jun 2010

22 Midwest facilities named Centers of Excellence in accelerated partial breast irradiation

Twenty-two facilities in the Midwest have been named Centers of Excellence in accelerated partial breast irradiation (APBI) for their use of the SAVI® applicator, an advanced therapy for breast cancer as part of breast conservation therapy. The SAVI applicator can provide important advantages for women with early-stage breast cancer.

10 Jun 2010

TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that pretargeted therapy with TF2, a bispecific antibody against carcinoembryonic antigen (CEA) and a small peptide, delayed tumor growth and prolonged survival in an animal model of human colonic cancer.

10 Jun 2010

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Abraxis BioScience, Inc. presented abstracts describing 10 trials of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), for the treatment of breast cancer at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

9 Jun 2010

White paper advocates strategies to reduce barriers to HPV vaccination, cervical cancer prevention

The Society of Gynecologic Oncologists has published its third in a series of four papers on a variety of cervical cancer issues and topics featured at "The Future Strategies for Cervical Cancer Prevention: What Do We Need to Do Now to Prepare" Forum. The paper, entitled "Can the Barriers to HPV Vaccination in High-Risk Populations be Overcome?" appears in the June, 2010 issue of Gynecologic Oncology Journal.

9 Jun 2010

Clinical results from the use of hyperthermia to treat cervical cancer presented at ESHO meeting

BSD Medical Corporation today reported significant clinical results from the use of hyperthermia to treat cervical cancer. The results were presented at the annual meeting of the European Society for Hyperthermic Oncology, which was held in Rotterdam, The Netherlands, on May 19 to 21, 2010.

9 Jun 2010

HPV-positive tumor status is strong prognostic factor for head, neck cancer

Oropharyngeal cancer patients whose tumors in the upper part of the throat test positively for the human papillomavirus (HPV) have better overall survival than patients with HPV-negative disease, researchers from The University of Texas MD Anderson Cancer Center report in a study published in The New England Journal of Medicine.

8 Jun 2010

Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010

OncoGenex Pharmaceuticals, Inc. today announced final results from a Phase 1 trial. The primary purpose of this trial was to evaluate the safety and tolerability of OGX-427 up to doses of 1000 mg for the treatment of various solid tumors. Patients enrolled had a diagnosis of castrate resistant prostate cancer, breast cancer, ovarian cancer or non-small cell lung cancer.

8 Jun 2010

Elekta Neuromag TRIUX system unveiled at Organization of Human Brain Mapping's Annual Meeting

At the Organization of Human Brain Mapping's 16th Annual Meeting (Barcelona, Spain, June 6-10), Elekta unveiled its next generation magnetoencephalography system, Elekta Neuromag TRIUX. A platform that addresses key requirements critical for monitoring normal and abnormal brain activity, Elekta Neuromag TRIUX was designed to operate in virtually any clinical environment – an advance welcomed by the growing number of Elekta Neuromag clinical and research facilities worldwide.

From Elekta 7 Jun 2010

OXiGENE reports positive final data from Phase 1 study of OXi4503 in patients with solid tumors

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that in collaboration with OXiGENE, Professor Gordon Rustin and colleagues from the Mount Vernon Cancer Research Centre, UK and other institutions in the United Kingdom, reported positive final data from an investigator-sponsored Phase 1 study of OXi4503 in patients with solid tumors.

7 Jun 2010

Celldex reports interim positive results from rindopepimut Phase 2b study for GBM at ASCO

Celldex Therapeutics, Inc. today announced that interim results from a Phase 2b study evaluating rindopepimut (formerly PF-04948568 or CDX-110) in newly-diagnosed glioblastoma multiforme (GBM) patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

7 Jun 2010

DOE program to develop new imager for improving reliability of cancer therapy using heavy-ion beams

In 2008 the Nuclear Science Division (NSD) of the U.S. Department of Energy's Lawrence Berkeley National Laboratory launched the Applied Nuclear Physics program, headed by NSD's Kai Vetter upon his return to Berkeley after six years with Lawrence Livermore National Laboratory. One of the goals of Applied Nuclear Physics is to take experimental principles and equipment created for basic research and develop them into tools that can address practical needs like cancer therapy and homeland security.

5 Jun 2010

New clinical research findings on oncology to be highlighted at ASCO 2010

Researchers from University Hospitals Case Medical Center's Ireland Cancer Center will present new clinical research findings at the 46th Annual Meeting of The American Society of Clinical Oncology June 4-8 in Chicago.

5 Jun 2010

Acute neurological toxicity associated with chronic neurological toxicity in patients with high-grade gliomas

Patients with high-grade gliomas who experience acute (early) neurological toxicity during their treatment were more likely to experience chronic (late) neurological toxicity and shortened overall survival, according to researchers from the Kimmel Cancer Center at Jefferson. The study will be presented at the 2010 ASCO Annual Meeting in Chicago (Abstract #2037).

5 Jun 2010

ASTRO to honor David Larson and William McBride with prestigious Gold Medal award

David Larson, M.D., Ph.D., FASTRO, and William McBride, D.Sc., Ph.D., have been chosen to receive the American Society for Radiation Oncology's most prestigious award, the Gold Medal. They will be presented with this honor at the Awards Ceremony during ASTRO's 52nd Annual Meeting, taking place October 31 to November 4, 2010, in San Diego.

4 Jun 2010

Discovery reveals a new approach to target cancer

Researchers at the University of Pittsburgh Cancer Institute (UPCI) and the School of Medicine have discovered that inhibiting a key molecule in a DNA repair pathway could provide the means to make cancer cells more sensitive to radiation therapy while protecting healthy cells.

3 Jun 2010

Radiation Therapy News and Research

Further Reading

Galera Therapeutics completes Series 1 financing

NBC's TODAY Show to focus on PF in an interview with a patient from California

Xoft reports clinical benefits of isotope-free electronic radiation therapy for treatment of cancer

HL survivors do not receive recommended cancer screening tests: Study

SBUMC uses RapidArc radiotherapy technology to treat cancer patients

22 Midwest facilities named Centers of Excellence in accelerated partial breast irradiation

TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer

Multiple presentations on nab-driven chemotherapy at 46th ASCO

White paper advocates strategies to reduce barriers to HPV vaccination, cervical cancer prevention

Clinical results from the use of hyperthermia to treat cervical cancer presented at ESHO meeting

HPV-positive tumor status is strong prognostic factor for head, neck cancer

Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010

Elekta Neuromag TRIUX system unveiled at Organization of Human Brain Mapping's Annual Meeting

OXiGENE reports positive final data from Phase 1 study of OXi4503 in patients with solid tumors

Celldex reports interim positive results from rindopepimut Phase 2b study for GBM at ASCO

DOE program to develop new imager for improving reliability of cancer therapy using heavy-ion beams

New clinical research findings on oncology to be highlighted at ASCO 2010

Acute neurological toxicity associated with chronic neurological toxicity in patients with high-grade gliomas

ASTRO to honor David Larson and William McBride with prestigious Gold Medal award

Discovery reveals a new approach to target cancer

Industry Focus eBook - Cell biology (5th edition) eBook

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News